2XB7

Structure of Human Anaplastic Lymphoma Kinase in complex with NVP- TAE684


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.243 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.195 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors.

Bossi, R.T.Saccardo, M.B.Ardini, E.Menichincheri, M.Rusconi, L.Magnaghi, P.Orsini, P.Avanzi, N.Borgia, A.L.Nesi, M.Bandiera, T.Fogliatto, G.Bertrand, J.A.

(2010) Biochemistry 49: 6813

  • DOI: 10.1021/bi1005514
  • Primary Citation of Related Structures:  
    2XB7, 2XBA

  • PubMed Abstract: 
  • Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-molecule inhibitors for the treatment of ALK-positive malignancies ...

    Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-molecule inhibitors for the treatment of ALK-positive malignancies. Here, we present the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684. Analysis of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors. In addition, the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded beta-sheet. Finally, mapping of the activating mutations associated with neuroblastoma onto our structures may explain the roles these residues have in the activation process.


    Organizational Affiliation

    Nerviano Medical Sciences S.r.l., Viale Pasteur 10, 20014 Nerviano (MI), Italy.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
ALK TYROSINE KINASE RECEPTORA315Homo sapiensMutation(s): 0 
Gene Names: ALK
EC: 2.7.10.1
Find proteins for Q9UM73 (Homo sapiens)
Explore Q9UM73 
Go to UniProtKB:  Q9UM73
NIH Common Fund Data Resources
PHAROS  Q9UM73
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GUI
Query on GUI

Download CCD File 
A
5-CHLORO-N-[2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PHENYL]-N'-(2-PROPAN-2-YLSULFONYLPHENYL)PYRIMIDINE-2,4-DIAMINE
C30 H40 Cl N7 O3 S
QQWUGDVOUVUTOY-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
GUIIC50:  10   nM  BindingDB
GUIIC50:  3   nM  BindingDB
GUIKi:  0.6499999761581421   nM  Binding MOAD
GUIKi :  0.6499999761581421   nM  PDBBind
GUIEC50:  3   nM  BindingDB
GUIIC50:  3.700000047683716   nM  BindingDB
GUIIC50:  0.15000000596046448   nM  BindingDB
GUIIC50:  4   nM  BindingDB
GUIKd:  1.100000023841858   nM  BindingDB
GUIIC50:  1.600000023841858   nM  BindingDB
GUIIC50:  10   nM  BindingDB
GUIIC50:  56   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.243 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.195 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.781α = 90
b = 57.307β = 90
c = 105.157γ = 90
Software Package:
Software NamePurpose
CNSrefinement
MOSFLMdata reduction
SCALAdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2010-07-28
    Type: Initial release
  • Version 1.1: 2011-05-08
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance